AGM
ACAD icon

Alpine Global Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Alpine Global Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-55,566
Closed -$1.02M – 132
2024
Q4 		$1.02M Buy
+55,566
New +$897K 0.3% 49

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Alpine Global Management's ACAD Position: Q1 2025 in Review

Alpine Global Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2025, closing a stake of 55,566 shares — an estimated $1.02M sold.

Alpine Global Management first reported a position in ACAD in Q4 2024 and held it in 1 quarter. The position peaked at $1.02M in Q4 2024. 320 funds tracked by Wall St. Rank hold ACAD as of Q1 2025.

  • Alpine Global Management reported no remaining Acadia Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Alpine Global Management sold 55,566 Acadia Pharmaceuticals shares in Q1 2025, an estimated $1.02M.
  • Alpine Global Management first reported a position in Acadia Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Alpine Global Management's Acadia Pharmaceuticals position peaked at $1.02M in Q4 2024.
  • 320 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2025.

Based on Alpine Global Management's 13F filing for Q1 2025, filed 15 May 2025.